Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.

Next Previous
Trial Profile

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Acute lung injury; Respiratory distress syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Faron Pharmaceuticals

Most Recent Events

  • 13 Jun 2016 Data from this trial were published in The Lancet Respiratory Medicine in 2014, according to a Faron Pharmaceuticals media release.
  • 20 May 2015 Results published in a Faron media release.
  • 16 Oct 2014 According to a Faron Pharmaceuticals, this study is part of Traumakine programm.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top